Horizon Discovery Group plc and Redx Pharma plc have announced a research collaboration to progress Redx’s novel pan-RAF inhibitor program, for out-licensing in oncology indications including colorectal cancer, the fourth most common cancer and the second most common cause of cancer death in the UK.
Redx’s pan-RAF inhibitor program has identified next generation novel small molecule inhibitors of RAF kinases as potential treatments for colorectal and other potential cancers. These next generation pan-RAF inhibitors have been designed to overcome resistance mechanisms seen with first generation RAF inhibitors in colorectal cancer.
As part of the collaboration, Horizon will deploy its proprietary gene editing, cell line and drug discovery technology platforms and know how to help explore the mode of action of Redx’s pan-RAF inhibitors and support Redx as it seeks to rapidly move this rare class of compounds towards partnering.
Under the terms of the agreement, Horizon and Redx will bear costs proportionate to respective research activities. The successful partnering of a program asset with a pharmaceutical company is expected to deliver a material return on Horizon’s investment from any upfront payment, a share of future milestones and a share of future product royalties.
Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery Group, commented: “Horizon’s expertise throughout the drug discovery and development continuum, from genomic sequence to patient treatment, enables pharmaceutical and biotech companies to address the challenges and hurdles that could prevent them from realizing the potential of their promising drug candidates. This partnership demonstrates how Horizon is able to strike innovative deals in which it deploys its proprietary technology platforms, know-how and internal resources to leverage significant upside potential for its shareholders.
“We are delighted to be able to support Redx as it moves towards securing partnerships for these novel assets and look forward to similar collaborations with other innovative drug development companies.”
Neil Murray, Chief Executive of Redx Pharma plc, commented: “Our pan-RAF inhibitor program is dealing with novel biology and is at a very interesting point. Our partnership with Horizon will enable us to detail at molecular level the effects of our pan-RAF inhibitors and help to progress this very promising program as we seek to secure a license partner for this asset.”